CI

At a glance

ClinicalIndex Comparison Record
N/AUnknown· 992 target
Drug / intervention
Fractional flow reserve, Coronary CT angiographyother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04547231
NCT04547231N/AUnknown

Impact of Stenosis and Plaque Features in Coronary CT Angiography, Physiologic Assessment and Pharmacotherapy on the Clinical Outcomes After Invasive Coronary Angiography

Seoul National University Hospital·observational·Posted Sep 14, 2020·Updated Mar 23, 2021

In Brief

An observational study evaluating Fractional flow reserve, Coronary CT angiography for Coronary Artery Disease. Targeting 992 participants across 1 site.

Detailed Summary

The investigators aim to investigate the prognostic implication of stenosis and plaque features on coronary CT angiography (CCTA), physiologic assessment, and pharmacotherapy after invasive coronary angiography.

Study Details

Timeline

N/AUnknownOverdue
202120222023202420252026
First PostedSep 14, 2020
Enrollment StartAug 12, 2020
Primary CompletionDec 31, 2024
Study CompletionDec 31, 2025
TodayJul 1, 2026
Enrollment to primary: 4.4 yearsPosted 5.8 years ago

Interventions

Fractional flow reserve, Coronary CT angiographyother

1. Coronary CT angiography (CCTA) and measurement of fractional flow reserve (FFR) will be performed as part of routine clinical practice. The decision to perform CCTA before invasive angiography was at the judgment of the physicians in charge. 2. Physiologic assessment includes delta FFR (lesion-specific) and FFR (vessel-specific) measurement. Delta FFR is defined as a pressure step up across the lesion. Coronary angiography and physiologic assessment will be analyzed by an independent core laboratory (Seoul National University Hospital, Clinical Trial Center, Seoul, South Korea). 3. Stenosis and plaque features on CCTA will be analyzed by an independent CCTA core laboratory (Severance Cardiovascular Hospital, Seoul, Korea), and pericoronary and epicardial fat metrics (fat attenuation index, epicardial fat attenuation index, epicardial fat volume, etc.) will be obtained by an independent cardiac CT fat core laboratory (Tsuchiura Kyodo general hospital, Ibaraki, Japan).